kebda iskandarani
Selected indexed studies
- Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial. (Lancet, 2025) [PMID:40897189]
- Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials. (Lancet, 2025) [PMID:40897188]
- Cardiovascular Outcomes of Uric Acid Lowering Medications: A Meta-Analysis. (Curr Cardiol Rep, 2024) [PMID:39352584]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial. (2025) pubmed
- Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials. (2025) pubmed
- Cardiovascular Outcomes of Uric Acid Lowering Medications: A Meta-Analysis. (2024) pubmed
- Impact of the COVID-19 Pandemic on Global TAVR Activity: The COVID-TAVI Study. (2024) pubmed
- Acupuncture in hematologic malignancies and hematopoietic cell transplantation. (2022) pubmed
- Mirizzi syndrome. (1985) pubmed
- Metabolically Healthy Obesity Is Characterized by a Distinct Proteome Signature. (2025) pubmed
- The effect of vericiguat on sudden cardiac death: insights from the VICTOR trial. (2026) pubmed
- Pregnancy in patients with pulmonary hypertension: a systematic review and meta-analysis with meta-regression. (2025) pubmed
- Tocilizumab in the Treatment of Eosinophilic Fasciitis: A Case Study and Review of Literature. (2023) pubmed